Clinical trials: Relapsed and Refractory Multiple Myeloma
Multiple Myeloma, Acute Myeloid Leukemia
A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies
This is a Phase 1 dose-escalation study of PRT1419, a myeloid cell leukemia 1 (MCL1) inhibitor, in patients with relapsed/refractory hematologic malignancies.
- Conditions
- Multiple Myeloma, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT04543305
- Testing
- PRT1419
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- Prelude Therapeutics Incorporated